Novel Non-Nucleotidic STING Agonists for Cancer Immunotherapy

Future Medicinal Chemistry - United Kingdom
doi 10.4155/fmc-2018-0367
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Future Science Ltd

Related search

Current Patent and Clinical Status of Stimulator of Interferon Genes (STING) Agonists for Cancer Immunotherapy

Pharmaceutical patent analyst
MedicineDrug DiscoveryPharmaceutical Science
2019English

Non‐viral Gene Delivery for Cancer Immunotherapy

Journal of Gene Medicine
Molecular MedicineDrug DiscoveryGeneticsMolecular Biology
2019English

Immunotherapy for Non-Small Cell Lung Cancer: Novel Approaches to Improve Patient Outcome: Erratum

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2012English

Radiotherapy as a Backbone for Novel Concepts in Cancer Immunotherapy

Cancers
Cancer ResearchOncology
2019English

Sonodynamic Therapy Assisted Immunotherapy: A Novel Modality for Cancer Treatment

Cancer Science
Cancer ResearchMedicineOncology
2018English

Mesothelin, a Novel Immunotherapy Target for Triple Negative Breast Cancer

Breast Cancer Research and Treatment
Cancer ResearchOncology
2012English

Laser-Photosensitizer Assisted Immunotherapy: A Novel Modality for Cancer Treatment

Cancer Letters
Cancer ResearchOncology
1997English

Immunotherapy for Gastrointestinal Cancer

Gastroenterology
HepatologyGastroenterology
2019English

Immunotherapy for Cervical Cancer

BioDrugs
MedicineBiotechnologyPharmacology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy